Published in Clin Infect Dis on March 15, 2009
A Multilevel Gaming Intervention for Persons on PrEP | NCT02611362
Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med (2013) 4.43
Rethinking prevention of HIV type 1 infection. Clin Infect Dis (2010) 4.19
HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial. Lancet Infect Dis (2014) 3.65
Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr (2010) 3.58
Limited Awareness and Low Immediate Uptake of Pre-Exposure Prophylaxis among Men Who Have Sex with Men Using an Internet Social Networking Site. PLoS One (2012) 2.82
High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP demonstration project. J Acquir Immune Defic Syndr (2015) 2.80
Sex frequency and sex planning among men who have sex with men in Bangkok, Thailand: implications for pre- and post-exposure prophylaxis against HIV infection. J Int AIDS Soc (2010) 2.70
Periconception pre-exposure prophylaxis to prevent HIV transmission: benefits, risks, and challenges to implementation. AIDS (2010) 2.70
Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. J Antimicrob Chemother (2010) 2.41
The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. Ann Intern Med (2012) 2.34
Evaluating the cost-effectiveness of pre-exposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa. PLoS One (2010) 2.30
A qualitative study of provider thoughts on implementing pre-exposure prophylaxis (PrEP) in clinical settings to prevent HIV infection. PLoS One (2012) 2.21
Sexual risk behaviors and acceptability of HIV pre-exposure prophylaxis among HIV-negative gay and bisexual men in serodiscordant relationships: a mixed methods study. AIDS Patient Care STDS (2011) 2.13
Antiretroviral agents used by HIV-uninfected persons for prevention: pre- and postexposure prophylaxis. Clin Infect Dis (2010) 2.07
The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res (2009) 2.03
The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies. PLoS Med (2013) 1.98
Transmission network parameters estimated from HIV sequences for a nationwide epidemic. J Infect Dis (2011) 1.98
Motivators, concerns, and barriers to adoption of preexposure prophylaxis for HIV prevention among gay and bisexual men in HIV-serodiscordant male relationships. AIDS Care (2011) 1.91
Implementation science of pre-exposure prophylaxis: preparing for public use. Curr HIV/AIDS Rep (2010) 1.90
Evolution of Massachusetts physician attitudes, knowledge, and experience regarding the use of antiretrovirals for HIV prevention. AIDS Patient Care STDS (2012) 1.86
Preexposure prophylaxis for adolescents and young adults at risk for HIV infection: is an ounce of prevention worth a pound of cure? Clin Infect Dis (2012) 1.86
The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women. Clin Infect Dis (2012) 1.80
HIV cure strategies: how good must they be to improve on current antiretroviral therapy? PLoS One (2014) 1.58
Sexual risk behavior among HIV-uninfected men who have sex with men participating in a tenofovir preexposure prophylaxis randomized trial in the United States. J Acquir Immune Defic Syndr (2013) 1.50
Engaging healthcare providers to implement HIV pre-exposure prophylaxis. Curr Opin HIV AIDS (2012) 1.48
Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection. J Infect Dis (2015) 1.45
Ambiguity, ambivalence, and apprehensions of taking HIV-1 pre-exposure prophylaxis among male couples in San Francisco: a mixed methods study. PLoS One (2012) 1.44
The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications. HIV Ther (2009) 1.41
Optimal costs of HIV pre-exposure prophylaxis for men who have sex with men. PLoS One (2017) 1.38
The potential impact of pre-exposure prophylaxis for HIV prevention among men who have sex with men and transwomen in Lima, Peru: a mathematical modelling study. PLoS Med (2012) 1.35
Initial commitment to pre-exposure prophylaxis and circumcision for HIV prevention amongst Indian truck drivers. PLoS One (2010) 1.31
Prevention of HIV infection among injection drug users in resource-limited settings. Clin Infect Dis (2010) 1.28
Factors influencing the emergence and spread of HIV drug resistance arising from rollout of antiretroviral pre-exposure prophylaxis (PrEP). PLoS One (2011) 1.26
Community member perspectives from transgender women and men who have sex with men on pre-exposure prophylaxis as an HIV prevention strategy: implications for implementation. Implement Sci (2012) 1.24
Preexposure prophylaxis for HIV prevention. Curr HIV/AIDS Rep (2011) 1.24
A US policy perspective on oral preexposure prophylaxis for HIV. Am J Public Health (2011) 1.20
HIV-AIDS: much accomplished, much to do. Nat Immunol (2013) 1.18
HIV-prevention science at a crossroads: advances in reducing sexual risk. Curr Opin HIV AIDS (2009) 1.18
Suboptimal awareness and comprehension of published preexposure prophylaxis efficacy results among physicians in Massachusetts. AIDS Care (2013) 1.11
Translating PrEP effectiveness into public health impact: key considerations for decision-makers on cost-effectiveness, price, regulatory issues, distributive justice and advocacy for access. J Int AIDS Soc (2015) 1.09
The impact of patient race on clinical decisions related to prescribing HIV pre-exposure prophylaxis (PrEP): assumptions about sexual risk compensation and implications for access. AIDS Behav (2014) 1.07
Antiretrovirals for primary HIV prevention: the current status of pre- and post-exposure prophylaxis. Curr HIV/AIDS Rep (2015) 1.04
HIV prevention by oral preexposure prophylaxis. Cold Spring Harb Perspect Med (2012) 1.03
Challenges for HIV pre-exposure prophylaxis among men who have sex with men in the United States. PLoS Med (2012) 1.02
Evaluating the impact of prioritization of antiretroviral pre-exposure prophylaxis in New York. AIDS (2014) 1.02
The Promise of Antiretrovirals for HIV Prevention. Curr Infect Dis Rep (2012) 1.02
Oral pre-exposure prophylaxis (PrEP) for prevention of HIV in serodiscordant heterosexual couples in the United States: opportunities and challenges. AIDS Patient Care STDS (2014) 1.02
Pre-exposure prophylaxis state of the science: empirical analogies for research and implementation. Curr HIV/AIDS Rep (2010) 1.01
Effectiveness and cost effectiveness of oral pre-exposure prophylaxis in a portfolio of prevention programs for injection drug users in mixed HIV epidemics. PLoS One (2014) 0.97
Study designs for identifying risk compensation behavior among users of biomedical HIV prevention technologies: balancing methodological rigor and research ethics. Soc Sci Med (2013) 0.96
Impact of the Centers for Disease Control's HIV Preexposure Prophylaxis Guidelines for Men Who Have Sex With Men in the United States. J Infect Dis (2016) 0.96
Clinical effectiveness and cost-effectiveness of HIV pre-exposure prophylaxis in men who have sex with men: risk calculators for real-world decision-making. PLoS One (2014) 0.95
Pre-exposure prophylaxis for the prevention of HIV infection in high risk populations: a meta-analysis of randomized controlled trials. PLoS One (2014) 0.92
Using geospatial modelling to optimize the rollout of antiretroviral-based pre-exposure HIV interventions in Sub-Saharan Africa. Nat Commun (2014) 0.91
Cost effectiveness of 'on demand' HIV pre-exposure prophylaxis for non-injection drug-using men who have sex with men in Canada. Can J Infect Dis Med Microbiol (2015) 0.90
Accuracy of highly sexually active gay and bisexual men's predictions of their daily likelihood of anal sex and its relevance for intermittent event-driven HIV pre-exposure prophylaxis. J Acquir Immune Defic Syndr (2015) 0.89
HIV Incidence Among Men Who Have Sex With Men After Diagnosis With Sexually Transmitted Infections. Sex Transm Dis (2016) 0.89
Brief Report: PrEP Uptake, Adherence, and Discontinuation Among California YMSM Using Geosocial Networking Applications. J Acquir Immune Defic Syndr (2017) 0.88
The price of tenofovir-emtricitabine undermines the cost-effectiveness and advancement of pre-exposure prophylaxis. AIDS (2011) 0.86
Paying for prevention: challenges to health insurance coverage for biomedical HIV prevention in the United States. Am J Law Med (2012) 0.85
Moving HIV pre-exposure prophylaxis into clinical settings: lessons from buprenorphine. Am J Prev Med (2013) 0.84
An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxis. Trials (2016) 0.83
Willingness to use pre-exposure prophylaxis for HIV prevention among female sex workers: a cross-sectional study in China. HIV AIDS (Auckl) (2012) 0.83
Promising prevention approaches: tenofovir gel and prophylactic use of antiretroviral medications. Curr HIV/AIDS Rep (2011) 0.83
Targeting pre-exposure prophylaxis among men who have sex with men in the United States and Peru: partnership types, contact rates, and sexual role. J Acquir Immune Defic Syndr (2015) 0.82
What do mathematical models tell us about the emergence and spread of drug-resistant HIV? Curr Opin HIV AIDS (2011) 0.82
Chemoprophylaxis for HIV prevention: new opportunities and new questions. J Acquir Immune Defic Syndr (2010) 0.82
HIV Treatment and Prevention: A Simple Model to Determine Optimal Investment. Med Decis Making (2015) 0.81
Analytic review of modeling studies of ARV Based PrEP interventions reveals strong influence of drug-resistance assumptions on the population-level effectiveness. PLoS One (2013) 0.81
HIV pre-exposure prophylaxis for people who inject drugs: a review of current results and an agenda for future research. J Int AIDS Soc (2014) 0.81
Cost-Effectiveness of HIV Preexposure Prophylaxis for People Who Inject Drugs in the United States. Ann Intern Med (2016) 0.80
Assessing the performance of a computer-based policy model of HIV and AIDS. PLoS One (2010) 0.79
Antiretroviral chemoprophylaxis: state of evidence and the research agenda. Clin Infect Dis (2014) 0.79
Pharmacists as providers of HIV pre-exposure prophylaxis. Int J Clin Pharm (2012) 0.79
Modeling and Cost-Effectiveness in HIV Prevention. Curr HIV/AIDS Rep (2016) 0.79
Towards an integrated framework for accelerating the end for the global HIV epidemic among young people. Sex Educ (2014) 0.77
HIV Incidence and Predictors of Incident HIV among Men Who Have Sex with Men Attending a Sexual Health Clinic in Melbourne, Australia. PLoS One (2016) 0.77
Pre-exposure prophylaxis of HIV: A right way to go or a long way to go? Artif Cells Nanomed Biotechnol (2014) 0.77
Strong propensity for HIV transmission among men who have sex with men in Vietnam: behavioural data and sexual network modelling. BMJ Open (2014) 0.76
Determining the Cost-Savings Threshold for HIV Adherence Intervention Studies for Persons with Serious Mental Illness and HIV. Community Ment Health J (2014) 0.76
ESTIMATING MEAN SURVIVAL TIME: WHEN IS IT POSSIBLE? Scand Stat Theory Appl (2015) 0.75
PrEP Implementation Science: State-of-the-Art and Research Agenda. J Int AIDS Soc (2015) 0.75
Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns. Drug Saf (2017) 0.75
Optimizing HIV pre-exposure prophylaxis implementation among men who have sex with men in a large urban centre: a dynamic modelling study. J Int AIDS Soc (2016) 0.75
Highlights from the 2012 International Symposium on HIV & Emerging Infectious Diseases (ISHEID): from cART management to the search of an HIV cure. AIDS Res Ther (2012) 0.75
Plasma Tenofovir-levels to Support Adherence to TDF/FTC Pre-exposure Prophylaxis for HIV Prevention in MSM in Los Angeles, California. J Acquir Immune Defic Syndr (2017) 0.75
The Potential Cost-Effectiveness of Pre-Exposure Prophylaxis Combined with HIV Vaccines in the United States. Vaccines (Basel) (2017) 0.75
Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med (2005) 42.71
Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet (2007) 38.98
Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet (2007) 37.69
Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis (2005) 10.20
Expanded screening for HIV in the United States--an analysis of cost-effectiveness. N Engl J Med (2005) 8.49
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med (2006) 8.35
Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med (2008) 7.46
Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal (1995) 7.45
Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet (2007) 7.22
The survival benefits of AIDS treatment in the United States. J Infect Dis (2006) 7.08
Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review. JAMA (2004) 7.04
The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med (2001) 5.89
The lifetime cost of current human immunodeficiency virus care in the United States. Med Care (2006) 5.87
Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med (2008) 5.81
Effects of a behavioural intervention to reduce acquisition of HIV infection among men who have sex with men: the EXPLORE randomised controlled study. Lancet (2004) 5.57
Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med (2006) 5.53
Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials (2007) 4.93
Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making (2000) 4.86
AIDS. Promote HIV chemoprophylaxis research, don't prevent it. Science (2005) 4.44
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS (2005) 4.07
What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med (2003) 3.88
Circumcision status and risk of HIV and sexually transmitted infections among men who have sex with men: a meta-analysis. JAMA (2008) 3.51
Men who have sex with men and women: a unique risk group for HIV transmission on North Carolina College campuses. Sex Transm Dis (2006) 3.34
Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston Community Health Center. J Acquir Immune Defic Syndr (2008) 3.10
Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study. Am J Epidemiol (2001) 2.69
Evaluation of initial CD4+ T cell counts in individuals with newly diagnosed human immunodeficiency virus infection, by sex and race, in urban settings. J Infect Dis (2002) 2.57
Pre-exposure prophylaxis for HIV infection: what if it works? Lancet (2007) 2.07
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr (2005) 1.87
A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J Acquir Immune Defic Syndr (2006) 1.76
Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. J Antimicrob Chemother (2007) 1.70
Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. JAMA (2004) 1.42
South Africa's experience of the closure of the cellulose sulphate microbicide trial. PLoS Med (2007) 1.40
Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am J Med Sci (2002) 1.37
Pre-exposure chemoprophylaxis (PREP) as an HIV prevention strategy. J Int Assoc Physicians AIDS Care (Chic) (2003) 1.27
Characteristics of recently HIV-infected men who use the Internet to find male sex partners and sexual practices with those partners. J Acquir Immune Defic Syndr (2006) 0.97
Acute renal failure in an HIV-positive 50-year-old man. Am J Kidney Dis (2000) 0.96
Antiretroviral therapy for prevention of HIV infection: new clues from an animal model. PLoS Med (2008) 0.90
HIV treatment proceeds as prevention research confounds. PLoS Med (2007) 0.84
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Expanded screening for HIV in the United States--an analysis of cost-effectiveness. N Engl J Med (2005) 8.49
The survival benefits of AIDS treatment in the United States. J Infect Dis (2006) 7.08
Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med (2004) 6.87
Surgery versus physical therapy for a meniscal tear and osteoarthritis. N Engl J Med (2013) 6.08
The lifetime cost of current human immunodeficiency virus care in the United States. Med Care (2006) 5.87
Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire. N Engl J Med (2006) 5.62
Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med (2006) 5.53
Loss to care and death before antiretroviral therapy in Durban, South Africa. J Acquir Immune Defic Syndr (2009) 5.40
Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis (2008) 5.14
The "ART" of linkage: pre-treatment loss to care after HIV diagnosis at two PEPFAR sites in Durban, South Africa. PLoS One (2010) 4.75
Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med (2013) 4.43
Association between hospital and surgeon procedure volume and the outcomes of total knee replacement. J Bone Joint Surg Am (2004) 4.42
Rates and outcomes of primary and revision total hip replacement in the United States medicare population. J Bone Joint Surg Am (2003) 4.38
When to start antiretroviral therapy in resource-limited settings. Ann Intern Med (2009) 4.31
Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med (2011) 4.21
Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J Virol (2004) 4.20
Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis (2010) 3.96
Who starts antiretroviral therapy in Durban, South Africa?... not everyone who should. AIDS (2010) 3.93
Cost-effectiveness of total knee arthroplasty in the United States: patient risk and hospital volume. Arch Intern Med (2009) 3.84
Sexual risk, nitrite inhalant use, and lack of circumcision associated with HIV seroconversion in men who have sex with men in the United States. J Acquir Immune Defic Syndr (2005) 3.54
CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr (2006) 3.39
Incidence rates of dislocation, pulmonary embolism, and deep infection during the first six months after elective total hip replacement. J Bone Joint Surg Am (2003) 3.33
Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis (2009) 3.30
Alcohol consumption and antiretroviral adherence among HIV-infected persons with alcohol problems. Alcohol Clin Exp Res (2004) 3.24
Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA (2006) 3.23
Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med (2013) 3.10
Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study. Clin Infect Dis (2008) 3.09
Early infant HIV-1 diagnosis programs in resource-limited settings: opportunities for improved outcomes and more cost-effective interventions. BMC Med (2011) 3.08
Association of hospital and surgeon volume of total hip replacement with functional status and satisfaction three years following surgery. Arthritis Rheum (2003) 2.98
Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis (2008) 2.96
Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA (2006) 2.96
Estimating the lost benefits of antiretroviral drug use in South Africa. J Acquir Immune Defic Syndr (2008) 2.93
Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann Intern Med (2004) 2.92
Routine voluntary HIV testing in Durban, South Africa: the experience from an outpatient department. J Acquir Immune Defic Syndr (2007) 2.91
Revising expectations from rapid HIV tests in the emergency department. Ann Intern Med (2008) 2.74
Epidemiology of total knee replacement in the United States Medicare population. J Bone Joint Surg Am (2005) 2.67
Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials. Clin Infect Dis (2014) 2.65
Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation (2008) 2.64
Randomized, controlled evaluation of a prototype informed consent process for HIV vaccine efficacy trials. J Acquir Immune Defic Syndr (2003) 2.60
Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med (2003) 2.48
HIV incidence determination in the United States: a multiassay approach. J Infect Dis (2012) 2.47
Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis (2005) 2.47
The quality of highly regarded adolescent substance abuse treatment programs: results of an in-depth national survey. Arch Pediatr Adolesc Med (2004) 2.45
Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis (2010) 2.45
Optimizing resource allocation in United States AIDS drug assistance programs. Clin Infect Dis (2006) 2.45
Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis. AIDS (2005) 2.39